ICU-Acquired Weakness Prevention: Current Strategies and Clinical Implications

Abstract

Intensive care unit-acquired weakness (ICU-AW) is a frequent and significant complication in critically ill patients, contributing to prolonged hospitalization, delayed rehabilitation, and increased morbidity. This review synthesizes current evidence on the prevention of ICU-AW, with a focus on epidemiology, pathophysiology, risk stratification, clinical recognition, and both established and emerging preventive interventions. Emphasis is placed on guideline-directed management, recent advances, and practical strategies for implementation in clinical settings to enhance patient outcomes and reduce disease burden.

Introduction

ICU-acquired weakness is a neuromuscular disorder that manifests as generalized muscle weakness in critically ill patients with no plausible etiology other than their acute illness or care environment. It is increasingly recognized due to its association with adverse clinical outcomes, including ventilator dependence, functional disability, and increased mortality. The prevention of ICU-AW has therefore become a priority in critical care medicine, necessitating a multidisciplinary approach informed by recent research and evolving clinical guidelines.

Epidemiology / Disease Burden

ICU-AW affects approximately 25–50% of patients admitted to intensive care units for more than one week, with higher incidence among those requiring mechanical ventilation or sepsis management. Studies reveal that ICU-AW prolongs ICU and hospital length of stay, increases healthcare costs, and contributes substantially to post-intensive care syndrome (PICS). The burden extends beyond the acute phase, with many survivors experiencing persistent physical impairment and reduced quality of life months to years after ICU discharge.

Pathophysiology

The underlying mechanisms of ICU-AW are multifactorial, involving both critical illness polyneuropathy (CIP) and myopathy (CIM). Pathogenesis includes systemic inflammatory response, microvascular dysfunction, mitochondrial impairment, bioenergetic failure, and upregulation of proteolytic pathways. Prolonged immobilization, hyperglycemia, and the use of certain medications exacerbate muscle catabolism and impair neuromuscular transmission. Disruption of cellular homeostasis leads to muscle atrophy, altered membrane excitability, and reduced regenerative capacity.

Risk Factors

Key risk factors for ICU-AW include sepsis, multi-organ failure, prolonged mechanical ventilation, immobility, hyperglycemia, and exposure to corticosteroids or neuromuscular blocking agents. Comorbidities such as diabetes mellitus, advanced age, and pre-existing malnutrition further amplify susceptibility. Early identification of high-risk patients is crucial for targeted preventive strategies.

Clinical Features

ICU-AW typically presents with symmetrical, flaccid weakness predominantly affecting proximal limb and respiratory muscles, sparing facial and ocular muscles. Reflexes may be diminished or absent. The diagnosis is often made when patients fail to wean from mechanical ventilation or demonstrate persistent functional deficits despite resolution of primary illness. Sensory involvement varies but is less prominent than motor deficits.

Diagnosis

Diagnosis of ICU-AW is clinical, based on the Medical Research Council (MRC) sum score, with a threshold of less than 48/60 indicating significant weakness. Electrophysiological studies, including nerve conduction and electromyography, may differentiate between CIP and CIM and exclude other causes of weakness. Exclusion of alternative pathologies, such as stroke or myasthenia gravis, is essential. Biomarkers and imaging are under investigation but are not routinely used.

Treatment & Management

The cornerstone of ICU-AW management is prevention, as no specific pharmacological therapies are currently available. Early mobilization and physiotherapy have robust evidence supporting their role in reducing incidence and severity. Glycemic control is vital, with current targets favoring moderate rather than intensive glucose management to balance efficacy and safety. Minimizing sedation, corticosteroid exposure, and neuromuscular blocking agents where feasible also contributes to risk reduction. Nutritional optimization and multidisciplinary rehabilitation are integral to comprehensive care.

Recent Advances / Emerging Therapies

Recent studies explore neuromuscular electrical stimulation (NMES) and early progressive mobilization protocols, demonstrating potential benefits in muscle strength preservation and functional outcomes. Pharmacological interventions targeting mitochondrial dysfunction, proteolysis, and inflammation are under investigation, though clinical translation remains limited. Digital health technologies, including wearable sensors and remote monitoring, are being evaluated for real-time assessment and personalized rehabilitation in ICU survivors.

Guideline Recommendations

International guidelines from the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) advocate for early assessment of neuromuscular function, daily sedation interruption, and structured mobilization programs. Glycemic control with a target of 140–180 mg/dL is recommended, and avoidance of unnecessary corticosteroids and paralytics is emphasized. Protocolized rehabilitation, regular re-evaluation, and interdisciplinary collaboration are endorsed to optimize prevention and recovery.

Conclusion

ICU-acquired weakness is a prevalent and debilitating complication of critical illness, with profound implications for patient outcomes and healthcare systems. Prevention relies on early mobilization, optimal glycemic management, judicious medication use, and guideline-directed multidisciplinary care. Ongoing research into novel therapies and personalized rehabilitation strategies holds promise for further reducing the burden of ICU-AW. Vigilant risk assessment and proactive intervention remain paramount in mitigating this syndrome and improving long-term functional recovery in ICU survivors.